“CRISPR Therapies Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CRISPR Therapies Market.
The CRISPR Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the CRISPR Therapies Pipeline Report:
Companies across the globe are diligently working toward developing novel CRISPR Therapies treatment therapies with a considerable amount of success over the years.
CRISPR Therapies companies working in the treatment market are Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others, are developing therapies for the CRISPR Therapies treatment
Emerging CRISPR Therapies therapies in the different phases of clinical trials are- BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others are expected to have a significant impact on the CRISPR Therapies market in the coming years.
In May 2025, Researchers at the University of Minnesota have completed the first human clinical trial using a CRISPR/Cas9 gene-editing method aimed at boosting the immune system’s ability to combat advanced gastrointestinal (GI) cancers. The findings, recently published in Lancet Oncology, demonstrate promising safety and potential effectiveness of the therapy. In this study, the team employed CRISPR/Cas9 to modify tumor-infiltrating lymphocytes (TILs), a type of immune cell. By disabling the CISH gene, the modified TILs showed an improved capacity to identify and attack cancer cells.
In January 2025, Scientists at the Experimental and Clinical Research Center (ECRC) in Berlin are advancing a targeted gene-editing therapy for muscular dystrophy. Preclinical studies conducted by the Spuler Lab, recently published in Nature Communications, have laid the groundwork for upcoming first-in-human clinical trials. The ECRC, a collaboration between the Max Delbrück Center and Charité – Universitätsmedizin Berlin, has created a promising gene-editing strategy aimed at restoring the function of a key protein vital for muscle repair and regeneration in patients suffering from muscular dystrophy.
CRISPR Therapies Overview
CRISPR therapies are a type of gene-editing treatment that use the CRISPR-Cas9 technology to precisely modify DNA within cells. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) allows scientists to target and correct faulty genes responsible for various genetic disorders. These therapies hold promise for treating conditions like sickle cell anemia, cancer, and certain inherited diseases by either repairing or disabling the problematic gene. CRISPR-based therapies are still largely in clinical trial phases but represent a revolutionary approach to personalized and potentially curative medicine.
Get a Free Sample PDF Report to know more about CRISPR Therapies Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/crispr-therapies-pipeline-insight
Emerging CRISPR Therapies Drugs Under Different Phases of Clinical Development Include:
BEAM-301: Beam Therapeutics
TNG260: Tango Therapeutics
CTX 130: CRISPR therapeutics
CB-010: Caribou Biosciences, Inc.
KSQ-4279: KSQ Therapeutics
NTLA-2002: Intellia Therapeutics, Inc.
LBP-EC01: Locus Biosciences
CTX001: CRISPR Therapeutic
CRISPR Therapies Route of Administration
CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type
CRISPR Therapies Molecule Type
CRISPR Therapies Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
CRISPR Therapies Pipeline Therapeutics Assessment
CRISPR Therapies Assessment by Product Type
CRISPR Therapies By Stage and Product Type
CRISPR Therapies Assessment by Route of Administration
CRISPR Therapies By Stage and Route of Administration
CRISPR Therapies Assessment by Molecule Type
CRISPR Therapies by Stage and Molecule Type
DelveInsight’s CRISPR Therapies Report covers around 30+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further CRISPR Therapies product details are provided in the report. Download the CRISPR Therapies pipeline report to learn more about the emerging CRISPR Therapies therapies
Some of the key companies in the CRISPR Therapies Therapeutics Market include:
Key companies developing therapies for CRISPR Therapies are – eGenesis, Intellia Therapeutics, Editas Medicine, Caribou Biosciences, Inscripta, Synthego, Inari, Ligandal, CRISPR Therapeutics, Mammoth Biosciences, Poseida Therapeutics, Beam Therapeutics, Pairwise, Sherlock Biosciences, and others
CRISPR Therapies Pipeline Analysis:
The CRISPR Therapies pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of CRISPR Therapies with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CRISPR Therapies Treatment.
CRISPR Therapies key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
CRISPR Therapies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CRISPR Therapies market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about CRISPR Therapies drugs and therapies
CRISPR Therapies Pipeline Market Drivers
New drugs are discovered employing the novel ways to treat diseases, CRISPR/Cas9 provides extensive opportunities for programmable gene editing are some of the important factors that are fueling the CRISPR Therapies Market.
CRISPR Therapies Pipeline Market Barriers
However, unwanted immune responses, off-target effects, CRISPR has tangible progress for localized administration and other factors are creating obstacles in the CRISPR Therapies Market growth.
Scope of CRISPR Therapies Pipeline Drug Insight
Coverage: Global
Key CRISPR Therapies Companies: Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others
Key CRISPR Therapies Therapies: BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others
CRISPR Therapies Therapeutic Assessment: CRISPR Therapies current marketed and CRISPR Therapies emerging therapies
CRISPR Therapies Market Dynamics: CRISPR Therapies market drivers and CRISPR Therapies market barriers
Request for Sample PDF Report for CRISPR Therapies Pipeline Assessment and clinical trials
Table of Contents
1. CRISPR Therapies Report Introduction
2. CRISPR Therapies Executive Summary
3. CRISPR Therapies Overview
4. CRISPR Therapies- Analytical Perspective In-depth Commercial Assessment
5. CRISPR Therapies Pipeline Therapeutics
6. CRISPR Therapies Late Stage Products (Phase II/III)
7. CRISPR Therapies Mid Stage Products (Phase II)
8. CRISPR Therapies Early Stage Products (Phase I)
9. CRISPR Therapies Preclinical Stage Products
10. CRISPR Therapies Therapeutics Assessment
11. CRISPR Therapies Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. CRISPR Therapies Key Companies
14. CRISPR Therapies Key Products
15. CRISPR Therapies Unmet Needs
16 . CRISPR Therapies Market Drivers and Barriers
17. CRISPR Therapies Future Perspectives and Conclusion
18. CRISPR Therapies Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
